PANGENOTYPIC HCV REGIMENS: ALL FOR ONE AND ONE FOR ALL
It’s no secret the incredible advancements in Hepatitis C treatment over the past 5 years, but it may come as a surprise that pangenotypic regimens are available. All patients, regardless of genotype (GT 1, 2, 3, 4, 5 or 6), can now be cured with an all-oral regimen in as little as 8 weeks. There are three pangenotypic regimens available with cure rates >95%. Epclusa (sofosbuvir/velpatasvir) and the recently approved Mavyret (pibrentasvir/glecaprevir) can be used for all patients, regardless of genotype and prior treatment experience. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) was also recently approved and is for patients who were previously treated with an NS5A inhibitor or patients with GT1a or GT3 who were previously treated with sofosbuvir with or without an NS5A inhibitor. With such amazing options, it’s hard to think that only a few years ago the only option was the dreaded combination of pegylated interferon and pegylated interferon and ribavirin.